Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT) A COG Groupwide Phase 3 Study
This is a phase III study using risk factors in determining treatment for children with favorable tissue (histology) Wilms tumors (FHWT). Wilms Tumor is the most common type of kidney cancer in children, and FHWT is the most common subtype. Patients will be divided into seven groups. Six groups of patients will receive chemotherapy medicine, and one group of patients will have a surgery called Nephrectomy done. The six groups will get the chemotherapy medicines as below:Group 1-(vincristine, dactinomycin), Group 2-( vincristine, dactinomycin, doxorubicin), Group 3- (vincristine, dactinomycin, irinotecan), Group 4- (vincristine, dactinomycin, doxorubicin, cyclophosphamide and etoposide), Group 5- (vincristine, dactinomycin, doxorubicin, cyclophosphamide, etoposide and irinotecan), and Group 6- (vincristine, doxorubicin, cyclophosphamide, etoposide, carboplatin and irinotecan). All patients will have blood samples taken to see how they are doing. All patients will have special scans taken to see how the study treatment is changing their cancer. The study team will closely monitor all patients for any side effects and safety concerns throughout the study.
Risk Evaluation, Assessment & Care for Hereditary Cancer Surveillance Program | NYU Langone Health
NYU Langone’s REACH Program offers cancer surveillance and risk management for those with genetic cancer risks or a family history of cancer.
Risk factors for sudden unexplained death in epilepsy (SUDEP)
The registry is a database created to document SUDEP (sudden unexplained death in epilepsy patients) cases. Our goals are to increase knowledge and awareness about epilepsy related mortality. We are interested in obtaining clinical records and DNA and/or brain tissue - on suspected SUDEP cases.
Risks & Benefits of Weight Loss Surgery | NYU Langone Health
At NYU Langone’s Weight Management Program, we educate patients on the most common risks and benefits of bariatric surgery for weight loss.
Robert I. Grossman, MD | NYU Langone Health
Dr. Robert I. Grossman is executive vice president to the Board of Trustees of NYU Langone Health.
Robotic-Assisted Surgery for Ureteral Stricture | NYU Langone Health
NYU Langone urologic surgeons have pioneered robotic-assisted surgery to correct ureteral stricture.
Robotic Mitral Valve Repair for Mitral Valve Disease | NYU Langone Health
NYU Langone cardiothoracic surgeons use robotic mitral valve repair to repair damaged mitral valves.
Robotic Orthopedic Surgery | NYU Langone Health
NYU Langone orthopedic surgeons specialize in robotic and computer-assisted surgical techniques for hip and knee replacement procedures.
Robotic Spine Surgery Program | NYU Langone Health
NYU Langone’s Robotic Spine Surgery Program uses robotic-assisted surgery to treat spine degeneration, misalignments, and other back and neck conditions.
Robotic Spine Surgery Program Doctors | NYU Langone Health
Find a doctor at the Robotic Spine Surgery Program at NYU Langone.